SeaBeLife Biotech

Executive Summary

SeaBeLife Biotech, a French pre-clinical biotechnology company founded in 2019, is pioneering first-in-class small molecule therapeutics that simultaneously inhibit necroptosis and ferroptosis—two key forms of regulated cell death. This dual-target approach aims to protect major organs in severe acute and chronic diseases with high unmet medical needs. The company's lead programs target dry age-related macular degeneration (AMD) and severe acute hepatitis, both conditions lacking effective disease-modifying therapies. By blocking these cell death pathways, SeaBeLife's platform has the potential to halt disease progression and preserve organ function. Located in Marseille, the company is advancing its candidates through preclinical development and is expected to seek IND-enabling studies and partnerships to move toward clinical trials. As a private entity with no disclosed funding, its progress depends on securing capital and achieving key preclinical milestones.

Upcoming Catalysts (preview)

• Q3 2026Preclinical efficacy data in dry AMD models40% success
• Q4 2026IND filing for lead program in severe acute hepatitis30% success
• Q2 2027Series A financing or strategic partnership50% success